MedTrace Logo

Changhai Multimodal Esophageal Cancer Cohort

NCT06410677 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2024-05-13

No results posted yet for this study

Summary

The burden of esophageal squamous cell carcinoma (ESCC) in China is substantial, with 85% of the cancers being in the progressive stage. The treatment for advanced ESCC are extremely limited, and immunotherapy, represented by PD-1 inhibitors, has demonstrated a promising application potential. However, the effectiveness of PD-1 inhibitors varies significantly among patients with different types of ESCC, and currently, there is no effective method to predict the response to PD-1 inhibitors. In this study, investigators aim to construct a multimodal deep learning-based model to predict the level of immune infiltration and the efficacy of immunotherapy for ESCC, integrating both pathological image features and clinical information of patients with ESCC, thereby enhancing the level of individualized and precise treatment for ESCC.

Conditions

Interventions

DIAGNOSTIC_TEST

DNA Sequencing, RNA Sequencing

High-coverage Whole-Exome Sequencing sequencing of DNA samples from ESCC was performed. RNA expression was analyzed using the NanoString PanCancer Immuno-Oncology 360TM Panel that includes a set of more than 700 genes involved in the main biological pathways of human immunity. These experiments were performed by the Genomics platform of Institut Curie. Total RNAs were used as templates.

Sponsors & Collaborators

  • Wangluowei

    lead OTHER

Principal Investigators

  • Luowei Wang · Changhai Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-13
Primary Completion
2022-10-21
Completion
2024-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06410677 on ClinicalTrials.gov